Figure 1

Figure 1

Zebrafish-based identification of neuroactive and antiseizure marine natural product (MNP) extracts. MNP extracts (crude extracts and fractions of pre-fractionated extracts) underwent a primary screen for neuroactivity at 100 µg/mL (2-h incubation time, n = 1), using the embryonic zebrafish photomotor response (PMR) assay, which was followed immediately after by a toxicity evaluation. Neuroactive hits (non-toxic) underwent a secondary screen for antiseizure activity at 100 µg/mL (2-h incubation time, n = 3), using the larval zebrafish pentylenetetrazole (PTZ) seizure model, which was followed immediately after by a toxicity evaluation. Antiseizure hits (non-toxic) underwent a second round of antiseizure analysis at 100, 33, and 11 µg/mL (2-h incubation time, n = 6) using the larval zebrafish PTZ seizure model, which was followed immediately after by a toxicity evaluation.